Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLEST: Zoledronic Acid in NSCLC with Bone Metastasis
NCT00765687Phase 4
Key facts
- Status
- Completed
- Start
- Aug 2008
- Primary completion
- May 2012
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Small Molecules
- Drugs
- zoledronic acid
- Conditions
- bone metastasis
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in bone metastasis, sponsored by Sun Yat-sen University. Primary endpoint: Skeleton-related event at 24 months. Started Aug 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Observation
Patients receiving zoledronic acid (Zometa) + Calcium/Vitamin D
03
Endpoints
Primary
Skeleton-related event
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT00765687.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00765687.